WallStSmart

Abbott Laboratories (ABT)vsAccenture plc (ACN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Accenture plc generates 60% more annual revenue ($72.11B vs $45.13B). ABT leads profitability with a 13.9% profit margin vs 10.6%. ACN appears more attractively valued with a PEG of 1.27. ACN earns a higher WallStSmart Score of 62/100 (C+).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

ACN

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 8.0Quality: 5.3
Piotroski: 3/9Altman Z: 2.79
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+0.6%)

Margin of Safety

+0.6%

Fair Value

$87.53

Current Price

$84.32

$3.21 discount

UndervaluedFair: $87.53Overvalued
ACNUndervalued (+35.7%)

Margin of Safety

+35.7%

Fair Value

$280.38

Current Price

$180.42

$99.96 discount

UndervaluedFair: $280.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

ACN4 strengths · Avg: 8.5/10
Market CapQuality
$111.04B9/10

Large-cap with strong market position

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

P/E RatioValuation
14.8x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$3.67B8/10

Generating 3.7B in free cash flow

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

ACN2 concerns · Avg: 3.5/10
EPS GrowthGrowth
4.0%4/10

4.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : ACN

The strongest argument for ACN centers on Market Cap, Return on Equity, P/E Ratio. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : ACN

The primary concerns for ACN are EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

ACN carries more volatility with a beta of 1.07 — expect wider price swings.

ACN is growing revenue faster at 8.3% — sustainability is the question.

ACN generates stronger free cash flow (3.7B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ACN scores higher overall (62/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Accenture plc

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Accenture plc is an Irish-domiciled multinational company that provides consulting and processing services. It has been incorporated in Dublin, Ireland since 2009.

Want to dig deeper into these stocks?